CING
Cingulate IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$69.31M
P/E Ratio
—
EPS
$-4.44
Beta
-0.77
52W High
$11.89
52W Low
$3.20
50-Day MA
$6.74
200-Day MA
$4.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders. The company is headquartered in Kansas City, Kansas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-9.77M |
| EBITDA | $-19.40M |
| Operating Margin | 0.00% |
| Return on Equity | -450.60% |
| Return on Assets | -83.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.35 |
| Price-to-Book | 28.62 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $11.63M |
| Float | $11.39M |
| % Insiders | 35.46% |
| % Institutions | 4.47% |
Historical Volatility
HV 10-Day
69.03%
HV 20-Day
173.52%
HV 30-Day
153.48%
HV 60-Day
128.01%
HV Rank
96.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($28.70 target)
1
Strong Buy2
BuyData last updated: 4/10/2026